611225-63-9Relevant articles and documents
Discovery of RAF265: A Potent mut-B-RAF inhibitor for the treatment of metastatic melanoma
Williams, Teresa E.,Subramanian, Sharadha,Verhagen, Joelle,McBride, Christopher M.,Costales, Abran,Sung, Leonard,Antonios-Mccrea, William,McKenna, Maureen,Louie, Alicia K.,Ramurthy, Savithri,Levine, Barry,Shafer, Cynthia M.,MacHajewski, Timothy,Renhowe, Paul A.,Appleton, Brent A.,Amiri, Payman,Chou, James,Stuart, Darrin,Aardalen, Kimberly,Poon, Daniel
supporting information, p. 961 - 965 (2015/09/22)
Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the treatment of pathway-dependent cancers. We report the development of imidazo-benzimidazoles as potent B-RAF inhibitors. Robust in
SOLID FORMS OF A RAF KINASE INHIBITOR
-
Page/Page column 56-57, (2009/01/20)
The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the sa
FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS
-
Page/Page column 26, (2008/06/13)
Formulations are provided, comprising: a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture